Cardiff Oncology, Inc.

NASDAQ:CRDF

Biotechnology

Healthcare
$0.84 +2.12%

+$0.03 today

Market cap
$65.27M
Beta
1.38
P/E (TTM)
-1.8
EPS (TTM)
-$0.65
52W Low $1.16High $4.56

Volume 0.86M

Average 1.05M

CRDF Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Cardiff Oncology, Inc.NASDAQ: CRDF

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $12.35M (cash outflow) fell 8.1% year over year, in line with the -8.4% change in trailing-twelve-month net income. Sequentially, it rose 71.1% from the prior quarter. Over 3 fiscal years it compounded at +5.8% a year.

Context

  • Net income amounted to 7732.0% of revenue in FY2025, up 1080.4 pp from a year earlier.
  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 5 analysts of -$39.95M (-12.9%) for the fiscal year ending Dec 2026, a slowdown from the +0.9% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$12.35M+71.1% QoQ
Last fiscal yearDec 2025
-$45.85M+0.9% YoY
LTMMar 2026
-$44.76M-8.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.1%-34.6%-26.5 pp
1 year+0.9%-12.9%-13.8 pp
3-year CAGR+5.8%+11.6%+5.8 pp
5-year CAGR-50.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(45.85M) USD
Year-over-year change
-0.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CRDF compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -8.4% is the 6th highest of 9, against a peer median of +3.6%.
  • Net income amounts to 8526.1% of revenue for CRDF, versus a peer median of 1764.5%.
CRDF Competitors
Net Income for CRDF and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$84.53M USD+68.1%+22.9%—
PEPGPepGen Inc.LTM Mar 2026$77.22M USD-24.4%+9.1%—
FBRXForte Biosciences, Inc.LTM Mar 2026$75.86M USD+73.5%+71.0%—
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$68.36M USD+31.7%+2.6%3832.0%
MOLNMolecular Partners AGLTM Mar 2026CHF 64.16M CHF+7.8%——
IPHAInnate Pharma S.A.FY2025€49.18M EUR-0.6%-5.4%1764.5%
CRDFCardiff Oncology, Inc.LTM Mar 2026$44.76M USD-8.4%+5.8%8526.1%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$40.19M USD-21.6%+11.9%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$31.7M USD-25.4%-22.3%1000.2%
Peer median (excluding CRDF) —+3.6%+9.1%1764.5%

Competitors are the stored peer set for CRDF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(28.29M)(38.7M)(41.44M)(45.43M)(45.85M)
Depreciation & Amortization451K236K398K404K904K
Deferred Income Tax1.32M0000
Stock-Based Compensation3.23M4.26M4.51M4.76M5.69M
Change in Working Capital(1.79M)(380K)6.57M3.17M2.18M
Accounts Receivables(215K)(236K)483K(484K)591K
Inventory00000
Accounts Payables719K1.35M2.83M2.99M2.2M
Other Working Capital(2.29M)(1.49M)3.25M671K(614K)
Other Non-Cash Items2.03M772K(921K)(598K)(848K)
Operating Cash Flow(23.04M)(33.82M)(30.89M)(37.69M)(37.92M)
Capital Expenditures(205K)(892K)(582K)(80K)(44K)
Acquisitions (Net)205K(114K)000
Purchases of Investments(174.39M)(91.23M)(70.08M)(23.56M)(71.12M)
Sales of Investments43.14M130.27M106.86M37.37M73.25M
Other Investing Activities(205K)114K00(744K)
Investing Cash Flow(131.45M)38.15M36.2M13.73M1.34M
Debt Repayment00000
Common Stock Issued34.19M75K053.41M2.58M
Common Stock Repurchased00000
Dividends Paid(24K)(414K)000
Other Financing Activities1.29M414K0373K0
Financing Cash Flow35.45M75K053.78M2.58M
Effect of Forex Changes00000
Net Change in Cash(119.04M)4.4M5.31M29.82M(34M)
Free Cash Flow(23.25M)(34.71M)(31.47M)(37.77M)(37.97M)

Cardiff Oncology, Inc.

NASDAQ:CRDF

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.